MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study

Reuters

Dec 30, 2025

MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study

MicroPort CardioFlow Medtech Corporation has announced the formal release of one-year follow-up results from the early feasibility study of AltaValveTM, a transcatheter mitral valve replacement (TMVR) device developed by its associated company, 4C Medical Technologies, Inc. The study, conducted across multiple centers in Europe, the United States, and Japan, enrolled 30 patients with symptomatic severe mitral regurgitation who were considered high surgical risk. The results have already been presented. The company has also recently completed a USD175 million Series D financing round to support global clinical trials and commercialization efforts for AltaValveTM. MicroPort CardioFlow Medtech Corporation holds exclusive commercial rights for AltaValveTM in Mainland China, Hong Kong, Macau, and Taiwan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251230-11971804), on December 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2595713548"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2595713548\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2595713548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595713548","market":"us","top_or_hot":-1,"title":"MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MicroPort CardioFlow Medtech Corporation has announced the formal release of one-year follow-up results from the early feasibility study of AltaValveTM, a transcatheter mitral valve replacement (TMVR) device developed by its associated company, 4C Medical Technologies, Inc. The study, conducted across multiple centers in Europe, the United States, and Japan, enrolled 30 patients with symptomatic severe mitral regurgitation who were considered high surgical risk. The results have already been presented. The company has also recently completed a USD175 million Series D financing round to support global clinical trials and commercialization efforts for AltaValveTM. MicroPort CardioFlow Medtech Corporation holds exclusive commercial rights for AltaValveTM in Mainland China, Hong Kong, Macau, and Taiwan.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MROPF\">Microport Cardioflow Medtech</a> Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251230-11971804), on December 30, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-30 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MicroPort CardioFlow Medtech Corporation has announced the formal release of one-year follow-up results from the early feasibility study of AltaValveTM, a transcatheter mitral valve replacement (TMVR) device developed by its associated company, 4C Medical Technologies, Inc. The study, conducted across multiple centers in Europe, the United States, and Japan, enrolled 30 patients with symptomatic severe mitral regurgitation who were considered high surgical risk. The results have already been presented. The company has also recently completed a USD175 million Series D financing round to support global clinical trials and commercialization efforts for AltaValveTM. MicroPort CardioFlow Medtech Corporation holds exclusive commercial rights for AltaValveTM in Mainland China, Hong Kong, Macau, and Taiwan.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MROPF\">Microport Cardioflow Medtech</a> Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251230-11971804), on December 30, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL4kMHmY:1","article_id":"2595713548","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595713548","pubTimestamp":1767105968,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MicroPort CardioFlow Medtech Corporation has announced the formal release of one-year follow-up results from the early feasibility study of AltaValveTM, a transcatheter mitral valve replacement  device developed by its associated company, 4C Medical Technologies, Inc. The study, conducted across multiple centers in Europe, the United States, and Japan, enrolled 30 patients with symptomatic severe mitral regurgitation who were considered high surgical risk. The results have already been presented. The company has also recently completed a USD175 million Series D financing round to support global clinical trials and commercialization efforts for AltaValveTM. MicroPort CardioFlow Medtech Corporation holds exclusive commercial rights for AltaValveTM in Mainland China, Hong Kong, Macau, and Taiwan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","02160":"微创心通-B","BK1100":"医疗保健设备","BK1589":"北水核心资产","BK1574":"生物医药B类股","00853":"微创医疗","BK1585":"昨日强势股"},"translate_title":"微创心通发布AltaValve TMVR早期可行性研究一年结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":0.9,"00853":0.9},"content_text":"MicroPort CardioFlow Releases One-Year Results from AltaValve TMVR Early Feasibility Study\n    \n\n        MicroPort CardioFlow Medtech Corporation has announced the formal release of one-year follow-up results from the early feasibility study of AltaValveTM, a transcatheter mitral valve replacement (TMVR) device developed by its associated company, 4C Medical Technologies, Inc. The study, conducted across multiple centers in Europe, the United States, and Japan, enrolled 30 patients with symptomatic severe mitral regurgitation who were considered high surgical risk. The results have already been presented. The company has also recently completed a USD175 million Series D financing round to support global clinical trials and commercialization efforts for AltaValveTM. MicroPort CardioFlow Medtech Corporation holds exclusive commercial rights for AltaValveTM in Mainland China, Hong Kong, Macau, and Taiwan.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251230-11971804), on December 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}